argenx

FINANCE AVENUE | NOVEMBER 2024

Reaching Patients Through Immunology Innovation

Forward Looking Statements

This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own internal estimates and research. While argenx believes these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of argenx's internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "aim," "continue," or "expects," and include statements argenx makes regarding its expansion efforts, including reaching more patients with VYVGART, through geographic expansion and into new autoimmune indications; the expectation that efgartigimod will have 15 indications in development by 2025; the anticipated development of empasiprubart and ARGX-119; the anticipated timing of its launch of SC efgartigimod for CIDP in the U.S.; the gaining market share among gMG treatments; the initiation, timing, progress and results of its anticipated clinical development, data readouts and regulatory milestones and plans; its strategic priorities, including the timing and outcome of regulatory filings and regulatory approvals; its expectation of sustainability and financial guidance for 2024, including with respect to its expected cash burn and combined research and development and selling, general and administrative expenses; the potential for innovation of its clinical programs; its pipeline; the nomination of new development candidates; the planned FDA submission for VYVGART SC pre-filled syringe by the end of June; the driving of patient growth with VYVGART Hytrulo; its continuation to drive transformational outcomes for patients, including by reaching new gMG patients, leveraging gMG know-how into future indications, and maximizing value creation and patient impact; its aim to address the unseen suffering in CIDP; and its long-term commitment to repeatable, sustainable and comprehensive value creation. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements in products and product candidates; the acceptance of argenx's products and product candidates by patients as safe, effective and cost-effective; the impact of governmental laws and regulations on our business; disruptions caused on our reliance of third parties suppliers, service provides and manufacturing; inflation and deflation and the corresponding fluctuations in interest rates; the results of the PDUFA review; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (the "SEC") filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this presentation, including any forward-looking statements, except as may be required by law.

This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners.

Est. 2008

argenx

Entrepreneurial spirit – calculated risk based on data

Immunology innovation through model of **co-creation**

Execution excellence

Building a Leading Immunology Company

Global Footprint



1,500+

Global employees and consultants

Rooted in Science

Immunology Innovation Program

Translating immunology breakthroughs into first-in-class pipeline opportunities

Wholly-Owned Pipeline

Efgartigimod	Empasiprubart	ARGX-119
FcRn Blocker	C2 Inhibitor	MuSK Agonist

Key Validating Partnerships

LEO · abbvie · Genmab · IQVIA · zai Lab

Reaching Patients

Global clinical programs ongoing in

VYVGART® (efgartigimod alfa-fcab)

VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)

VYVGART first-approved FcRn blocker in US, Japan, China, Canada, EU, UK, Israel

50,000

Patients by 2030

argenx

Innovation has no meaning unless it reaches patients and provides real benefit

Our Innovation Playbook



Our Innovation Horizons

PIPELINE

- ARGX-109 (Anti-IL-6)
- ARGX-213 (Anti-FcRn)
- ARGX-121 (Anti-IgA)
- ARGX-220
- ARGX-119
- CMS
- ALS
- Future Indications
- Empasiprubart
- MMN
  Established PoC
- DGF
- DM
- CIDP
- Future Indications

iip immunology innovation program

VYVGART Opportunity

- VYVGART® (efgartigimod alfa-fcab)
  Injection for Intravenous Use
  400 mg/20 mL vial
- VYVGART® Hytrulo
  (efgartigimod alfa and hyaluronidase-qvfc)
  Subcutaneous Injection
  180 mg/mL and 2000 U/mL vial
- **$573M** in gMG and CIDP revenue in Q3 2024
- CIDP launched
- ITP launched
- 5 registrational trials by YE 2024: oMG, snMG, TED, SjD, ITP-US
- **PFS** MG, CIDP
  PDUFA April, 2025

Delivering Innovation Across VYVGART Globally

Driving impact with VYVGART

MG Rapid, deep, sustained responses achieved in patients

54%
MSE[1]

42%
TAPERED TO ≤ 5 MG STEROIDS[2]

25%
TAPERED TO 0 MG STEROIDS[2]

CIDP Consistent responses and regain of function



Reaching Patients Globally with VYVGART Franchise

>10,000 patients on treatment[1]

VYVGART and VYVGART Hytrulo[2] approved across
3 continents within one calendar year

1.ADAPT/ADAPT+ combined real world and clinical data
2. IQVIA Claims analysis: 1-year post efgartigimod initiation

Driving Patient Growth with VYVGART

PATIENT GROWTH

60%

Hytrulo patients new to VYVGART YTD [2]

Expanding VYVGART Hytrulo share

EARLIER LINE PATIENTS

~60%

New VYVGART patients coming from orals[1]

US patients

PRESCRIBER EXPANSION

>3k

Total VYVGART prescribers[1]

Breadth of prescribers

PATIENT EXPERIENCE

PFS

PDUFA April 10th

Expanding patient reach

1. VYVGART and VYGART Hytrulo
2. VYVGART Hytrulo only

We Aim to Address the Unseen Suffering in CIDP



≤20% of patients achieve remission on current SOC (CDAS=2)*

>50% of patients are dissatisfied with their symptom burden**

>88% of treated patients report residual neurological symptoms, including muscle weakness, sensory symptoms, pain, and fatigue ***

>42K treated CIDP patients in US & ROW argenx markets (ex-China)****

*Gorson KC, et al. 2010
** Mendoza M, et al. 2023
***Bunschoten C et al. 2019
**** argenx market research

This is **Just the Beginning**

Phase 3 studies | **2024 PoC studies** | **Beyond 2024 PoC studies**

- sn gMG oMG
- TED **100K**
- ITP-US **57K**
- Sjogren's **330K** ●
- IMNM **6K**
- BP **52K**
- ASyS **11K**
- DM **70K**
- LN **40K**
- MN **80K**
- AMR **8K**
- SSc **60K**
- …

MG
Launched 2022
80K

CIDP
Approved June 21, 2024
42K

ITP
Approved in Japan | March 26, 2024
17K

REMAINING READOUTS IN 2024
Myositis
Bullous Pemphigoid

● On track for 2024 Ph3 start

argenx market research; US prevalence numbers (except Japan ITP), sn gMG and oMG are in-market expansion studies

Product Net Sales: Q3 of $573 million



Q3 2024: growth of 74% vs Q3 2023

(in millions of $)	Q3 2024	Q3 2023	Growth % *
US	492	280	76%
Japan	24	15	49%
ROW	46	26	76%
China supply	11	7	44%
Total	**573**	**329**	74%

Q3 2024: growth of 20% vs Q2 2024

(in millions of $)	Q3 2024	Q2 2024	QoQ % Growth *
US	492	407	21%
Japan	24	20	20%
ROW	46	36	28%
China supply	11	14	(21)%
Total	**573**	**478**	20%
Total excluding China	**562**	**464**	21%

*Net sales growth % excludes the impact of fx.

argenx

VYVGART® (efgartigimod alfa-fcab) Injection for Intravenous Use 400 mg/20 mL vial

VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial

Opportunities Ahead Strengthen Our Leadership



Our Innovation Horizons

ARGX-109
(Anti-IL-6)

ARGX-213
(Anti-FcRn)

ARGX-121
(Anti-IgA)

ARGX-220

ARGX-119

CMS

ALS

Future Indications

Empasiprubart

MMN
Established PoC

DGF

DM

CIDP

Future Indications

PIPELINE

VYVGART®
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial

VYVGART® Hytrulo
(efgartigimod alfa and hyaluronidase-qvfc)
Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

$573M in gMG and CIDP revenue in Q3 2024

CIDP launched

ITP launched

5 registrational trials by YE 2024: oMG, snMG, TED, SjD, ITP-US

PFS MG, CIDP
PDUFA April, 2025

VYVGART Opportunity

iip immunology innovation program

Vision 2030

5 New Molecules in Phase 3

10 Labeled Indications

50k Patients on Treatment

COMMITMENT TO OUR TRANSFORMATION MISSION

- Continuous Pipeline of Innovation
- Leadership in FcRn
- Disciplined Scaling